维多利亚老品牌76696vic-在线入口

Be the most trusted biotech company

2023-12-13

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Ipilimumab Biosimilar HLX13
2023-12-12

The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA
2023-12-05

Henlius Receives "Listed Enterprises 2023" Award from Bloomberg Businessweek/Chinese Edition
2023-12-04

Results from Four Phase 1/2 Clinical Trials of Henlius’ Innovative Products Released at 2023 ESMO Asia
2023-12-04

Results from the Phase 2 Clinical Trial of Henlius BRAF Inhibitor HLX208 for the Treatment of LCH and/or ECD Released at 2023 ESMO Asia
2023-12-04

Results of the Asian Subgroup in Phase 3 Clinical Study of Novel Anti-PD-1 mAb HANSIZHUANG for the First-Line Treatment of sqNSCLC Released at ESMO Asia 2023
2023-11-28

Henlius Xuhui Facility Passes Colombian GMP Inspection for HANLIKANG
2023-11-27

Henlius Receives the FDA IND Approval for Its PD-L1-Targeting ADC Candidate HLX43
2023-11-24

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ ADC Candidate HLX43